Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials

Neuro-Oncology

Volumn 17, Issue 8, 2015, Pages 1106-1113

  Trippa, Lorenzo ^a,b   Wen, Patrick Y ^c   Parmigiani, Giovanni ^a,b   Berry, Donald A ^d   Alexander, Brian M ^c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adaptive clinical trials; Auxiliary endpoints; Clinical trial; Endpoints; Overall survival; Progression free survival

Indexed keywords

ACCURACY; ALGORITHM; ARTICLE; CALCULATION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; GLIOBLASTOMA; HUMAN; MATHEMATICAL ANALYSIS; OVERALL SURVIVAL; PROBABILITY; PROGRESSION FREE SURVIVAL; RANDOMIZATION; SIMULATION; STATISTICAL MODEL; SURVIVAL RATE; BIOASSAY; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; GLIOBLASTOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MODELS, STATISTICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84928922288     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou345     Document Type: Article

References (20)

1. Quant EC, Drappatz J, Wen PY, et al. Recurrent high-grade glioma. Curr Treat Options Neurol. 2010;12(4):321-333.
2. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008; 359(5):492-507.
3. Steensma DP, Kantarjian HM. Impact of cancer research bureaucracy on innovation, costs, and patient care. J Clin Oncol. 2014;32(5):376-378.
4. Han K, Ren M, Wick W, et al. Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials. Neuro Oncol. 2014;16(5):696-706.
5. Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst. 2009; 101(23):1642-1649.
6. Alexander BM, Trippa L. Progression-free survival: too much risk, not enough reward? Neuro Oncol. 2014;16(5):615-616.
7. Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709-722.
8. Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699-708.
9. Thall PF, Wathen JK. Practical Bayesian adaptive randomisation in clinical trials. Eur J Cancer. 2007;43(5):859-866.
10. Berry DA. Adaptive clinical trials: the promise and the caution. J Clin Oncol. 2011;29(6):606-609.
11. Trippa L, Lee EQ, Wen PY, et al. Bayesian adaptive randomized trial design for patients with recurrent glioblastoma. J Clin Oncol. 2012; 30(26):3258-3263.
12. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963-1972.
13. Brandes AA, Franceschi E, Tosoni A, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol. 2008; 26(13):2192-2197.
14. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
15. Rosenberger WF, Hu F. Bootstrap methods for adaptive designs. Stat Med. 1999;18(14):1757-1767.
16. Trippa L, Rosner GL, Muller P. Bayesian enrichment strategies for randomized discontinuation trials. Biometrics. 2012;68(1): 203-211.
17. Ballman KV, Buckner JC, Brown PD, et al. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol. 2007;9(1):29-38.
18. Polley MY, Lamborn KR, Chang SM, et al. Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide. Neuro Oncol. 2010;12(3):274-282.
19. Barker AD, Sigman CC, Kelloff GJ, et al. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther. 2009;86(1):97-100.
20. Gilbert MR, Wang M, Aldape KD, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol. 2013;31(32):4085-4091.